Navigation Links
PTC Therapeutics' President and CEO Elected AAAS Fellow

SOUTH PLAINFIELD, N.J., Jan. 19, 2011 /PRNewswire/ -- Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.  AAAS Fellows are chosen by their peers and recognized for their scientifically or socially distinguished efforts to advance science or its applications.


As part of the Biological Science Section, Dr. Peltz is recognized for his "distinguished contributions in the area of genetics and RNA biochemistry, specifically mRNA stability and decay."  Dr. Peltz co-founded PTC Therapeutics in 1998 with the goal of discovering, developing and commercializing innovative therapies in areas of high unmet medical need based on RNA biochemistry and post-transcriptional control mechanisms.  While a total of 503 Fellows were recognized for 2010, Dr. Peltz is one of only ten Fellows elected who are currently in industry.  

"On behalf of the Board and the broader PTC community, we all congratulate Stuart for the AAAS Council's recognition for the excellence and value of his work in genetics and RNA biochemistry.  We all agree this is well deserved," said Michael Schmertzler, Chairman of the Board of Directors of PTC Therapeutics.

The tradition of AAAS Fellows began in 1874.  Currently, members can be considered for the rank of Fellow if nominated by the steering groups of the Association's 24 sections, or by any three Fellows who are current AAAS members, or by the AAAS chief executive officer.  Each steering group then reviews the nominations of individuals within its respective section and forwards a final list to the AAAS Council.  The AAAS Council, the association's policymaking body, votes on the final list.

"This is a great honor, for which a very large portion of the credit goes to my students, collaborators, colleagues and employees at PTC," said Dr. Stuart Peltz, President and CEO.  "We are committed to applying innovative science to develop therapies for diseases that currently have little or no treatment options."  

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes.  Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and is the basis for collaborations with leading biopharmaceutical companies.  For more information, visit the company's web site at

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
2. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
3. Echo Therapeutics to Present at the OneMedForum 2011 Conference
4. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
5. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
6. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
7. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
9. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
10. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
11. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... , ... Doctors who missed a case of mesothelioma in a 70-year-old Japanese ... push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma has just ... now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan say the ...
(Date:11/28/2015)... ... November 28, 2015 , ... ... teleradiology services, has added Chris Hafey and Claude Hooton to its board of ... Society of North America (RSNA) 2015 Annual Meeting and continues to strategically transform ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):